精准神经肿瘤学时代框架立体定向活检的分子诊断率:一项横断面研究
该研究回顾性纳入2020至2021年连续接受框架立体定向活检的颅内病变患者145例,评估诊断成功率。137例(94.5%)获得确定性诊断,3例(2.0%)诊断成立但缺乏分子遗传学数据,5例(3.5%)诊断不确定。DNA不足与诊断不确定或缺乏分子遗传学数据相关(p < 0.001)。
要点
- 145例框架立体定向活检中94.5%获得确定性诊断
- 3.5%诊断不确定,2.0%诊断成立但缺乏分子遗传学数据
- DNA不足与诊断不确定或分子数据缺失相关(p < 0.001)
核心结论
- 框架立体定向活检虽取材有限,但组织病理学和分子遗传学诊断率较高。
- 鉴于计划活检轨迹的手术精度已证实,优化所探查的病变区域可能有助于提高确定性诊断率。
研究设计与样本
- 回顾性分析纳入2020年和2021年连续接受框架立体定向活检的颅内病变患者。
- 病例分为三组:确定性诊断、诊断成立但缺乏分子遗传学数据、神经病理诊断不确定。
主要发现
- 145例患者中137例(94.5%)获得确定性诊断,3例(2.0%)诊断成立但缺乏分子遗传学数据,5例(3.5%)诊断不确定。
- 诊断主要包括WHO 4级胶质母细胞瘤73例(56%)、中枢神经系统淋巴瘤23例(16%)、炎性疾病14例(10%)和转移瘤5例(3%)。
- 肿瘤病例中49%(44例)应用了甲基化组学分析,28例(占肿瘤的30%)进行了panel测序。
- 用于分子遗传学诊断的标本平均数量为5,而提供的标本平均数量为15。
- 单因素分析中,DNA不足与诊断不确定或诊断成立但缺乏分子遗传学数据相关(p < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the increasing role of molecular genetics in the diagnostics of intracranial tumors, delivering sufficient representative tissue for such analyses is of paramount importance. This study explored the rate of successful diagnosis after frame-based stereotactic biopsies of intracranial lesions. METHODS: Consecutive patients undergoing frame-based stereotactic biopsies in 2020 and 2021 were included in this retrospective analysis. Cases were classified into three groups: conclusive, diagnosis with missing molecular genetics (MG) data, and inconclusive neuropathological diagnosis. RESULTS: Of 145 patients, a conclusive diagnosis was possible in n = 137 cases (94.5%). For 3 cases (2.0%), diagnosis was established with missing MG data. In 5 cases (3.5%), an inconclusive (tumor) diagnosis was met. Diagnoses comprised mainly WHO 4 glioblastomas (n = 73, 56%), CNS lymphomas (n = 23, 16%), inflammatory diseases (n = 14, 10%), and metastases (n = 5, 3%). Methylomics were applied in 49% (n = 44) of tumor cases (panel sequencing in n = 28, 30% of tumors). The average number of specimens used for MG diagnostics was 5, while the average number of specimens provided was 15. In a univariate analysis, insufficient DNA was associated with an inconclusive diagnosis or a diagnosis with missing MG data (p < 0.001). Analyses of planned and implemented trajectories of cases with diagnosis with missing MG data or inconclusive diagnosis (n = 8) revealed that regions of interest were reached in almost all cases (n = 7). CONCLUSION: Although stereotactic frame-based biopsies deliver a limited amount of tissue, they bear high histopathological and molecular genetic diagnostic yields. Given the proven surgical precision of the planned biopsy trajectories, optimizing surveyed lesion regions could help improve the rate of conclusive diagnoses.
引用
- Alhalabi OT, Sahm F, Unterberg AW, et al. The molecular diagnostic yield of frame-based stereotactic biopsies in the age of precision neuro-oncology: a cross-sectional study. Acta Neurochir (Wien). 2023. PMID: 37553446. doi:10.1007/s00701-023-05742-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。